Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Eisai Ltd ADR (OP: ESALY ) N/A UNCHANGED Last Price Updated: 3:59 PM EST, Jan 30, 2023 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Eisai Ltd ADR Biogen Shares Fall After FDA Approval Of Alzheimer's Drug Leqembi July 10, 2023 Biogen's shares decline after approval of Alzheimer's treatment Leqembi, which modestly slows cognitive decline. Analysts see hurdles to the rollout. Via MarketBeat Exposures Product Safety Lecanemab Receives Priority Review Status in Japan January 29, 2023 From Eisai Via JCN Newswire Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease January 09, 2023 From Eisai Via JCN Newswire FDA Approves LEQEMBI (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease January 09, 2023 From Eisai Via JCN Newswire Astellas, Eisai, Daiichi Sankyo and Takeda Agree to Collaborate to Reduce Environmental Burden in the Field of Pharmaceutical Packaging December 22, 2022 From Eisai Via JCN Newswire Eisai to Divest Rights for Anti-Epileptic Drug Fycompa (perampanel) CIII in United States to Catalyst Pharmaceuticals December 19, 2022 From Eisai Via JCN Newswire Eisai to Present Preclinical and Clinical Research on Eribulin at the 2022 San Antonio Breast Cancer Symposium December 01, 2022 From Eisai Via JCN Newswire Eisai Announces Approval of Partial Change to Label for Dosage and Administration of Aricept for Treatment of Dementia with Lewy Bodies November 29, 2022 From Eisai Via JCN Newswire Eisai to Present Latest Data on Perampanel at the 76th American Epilepsy Society (AES) Annual Meeting November 23, 2022 From Eisai Via JCN Newswire Eisai and Washington University School of Medicine in St. Louis Enter Into Comprehensive Research Collaboration Agreement Aiming to Create New Therapies for Neurodegenerative Diseases December 14, 2022 From Eisai Via JCN Newswire Eisai Presents Full Results of Lecanemab Phase 3 Confirmatory Clarity Ad Study for Early Alzheimer's Disease at Clinical Trials on Alzheimer's Disease (CTAD) Conference November 29, 2022 From Eisai Via JCN Newswire Eleven Experts from Leading Medical Institutions and Eight Experts from Eisai Publish Full Results of Lecanemab Phase 3 Confirmatory Clarity Ad Study for Early Alzheimer's Disease in the New England Journal of Medicine November 29, 2022 From BiogenEisai Via JCN Newswire To Develop Japan's First Blood Biomarker-Based Diagnostic Workflow for Dementia Shimadzu, Eisai, Oita University, and Usuki City Medical Association Commence Joint Research November 22, 2022 From Eisai Via JCN Newswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.